Skip to main content
Erschienen in: Der Gastroenterologe 3/2013

01.04.2013 | Schwerpunkt

Therapie der extraintestinalen CED-Manifestationen

Eine schwierige Herausforderung

verfasst von: J. Zeitz, PD Dr. S.R. Vavricka

Erschienen in: Die Gastroenterologie | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Morbus Crohn und Colitis ulcerosa sind chronisch-entzündliche Darmerkrankungen (CED), die nicht auf das Gastrointestinalsystem beschränkt sind. Zusätzlich können diverse Organsysteme mit betroffen sein, was die CED zu einer Systemerkrankung macht. Die häufigsten extraintestinalen Manifestationen beinhalten muskuloskelettale, ophthalmologische, dermatologische und hepatobiliäre Erkrankungen, obwohl prinzipiell jedes Organsystem betroffen sein kann. Sie können signifikant zur Morbidität von CED-Patienten beitragen und die Lebensqualität deutlich einschränken. Die Betreuung sollte aufgrund der Vielfalt der betroffenen Organsysteme interdisziplinär durch ein in der CED-Behandlung geschultes medizinisches Personal erfolgen. Ein frühes Erkennen von extraintestinalen Manifestationen ermöglicht eine gezielte Therapie und verringert die Gesamtmorbidität der betroffenen Patienten. Insbesondere kann eine effektive Erhaltungstherapie das Auftreten von Manifestationen, die eng mit der Krankheitsaktivität der zugrunde liegenden CED verknüpft sind, vermeiden helfen. Neben spezifischen Interventionen, die nicht mit der Krankheitsaktivität der CED verknüpft sind, spielt eine antiinflammatorische oder immunmodulatorische Therapie eine entscheidende Rolle. Zudem gewinnt die Verwendung einer TNF-Hemmer-Therapie in der Behandlung von verschiedenen extraintestinalen Manifestationen zunehmend an Bedeutung.
Literatur
1.
Zurück zum Zitat Peyrin-Biroulet L et al (2011) Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis 17: 471–478PubMedCrossRef Peyrin-Biroulet L et al (2011) Long-term complications, extraintestinal manifestations, and mortality in adult Crohn’s disease in population-based cohorts. Inflamm Bowel Dis 17: 471–478PubMedCrossRef
2.
Zurück zum Zitat Lakatos L et al (2003) Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 9: 2300–2307PubMed Lakatos L et al (2003) Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 9: 2300–2307PubMed
3.
Zurück zum Zitat Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106: 110–119PubMedCrossRef Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106: 110–119PubMedCrossRef
4.
Zurück zum Zitat Bernstein CN et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96: 1116–1122PubMedCrossRef Bernstein CN et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96: 1116–1122PubMedCrossRef
5.
Zurück zum Zitat Bernstein CN (2002) Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 4: 513–516PubMedCrossRef Bernstein CN (2002) Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 4: 513–516PubMedCrossRef
6.
Zurück zum Zitat Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42: 387–391PubMedCrossRef Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42: 387–391PubMedCrossRef
7.
Zurück zum Zitat Russell AS (1977) Arthritis, inflammatory bowel disease, and histocompatibility antigens. Ann Intern Med 86: 820–821PubMedCrossRef Russell AS (1977) Arthritis, inflammatory bowel disease, and histocompatibility antigens. Ann Intern Med 86: 820–821PubMedCrossRef
8.
Zurück zum Zitat Van Assche G et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis 4: 63–101CrossRef Van Assche G et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis 4: 63–101CrossRef
9.
Zurück zum Zitat Van Assche G et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. J Crohn’s colitis Van Assche G et al (2012) Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. J Crohn’s colitis
10.
Zurück zum Zitat Singh S, Graff LA, Bernstein CN (2009) Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 104: 1298–1313 (quiz 1314)PubMedCrossRef Singh S, Graff LA, Bernstein CN (2009) Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 104: 1298–1313 (quiz 1314)PubMedCrossRef
11.
Zurück zum Zitat Lakatos PL et al (2012) Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion, 86(Suppl 1): 28–35 Lakatos PL et al (2012) Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion, 86(Suppl 1): 28–35
12.
Zurück zum Zitat Herfarth H et al (2002) Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 97: 2688–2690PubMedCrossRef Herfarth H et al (2002) Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. Am J Gastroenterol 97: 2688–2690PubMedCrossRef
13.
Zurück zum Zitat Kaufman I et al (2005) The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 25: 406–410PubMedCrossRef Kaufman I et al (2005) The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 25: 406–410PubMedCrossRef
14.
Zurück zum Zitat Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65: 423–432PubMedCrossRef Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65: 423–432PubMedCrossRef
15.
Zurück zum Zitat Ardizzone S et al (2008) Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40(Suppl 2): S253–S259PubMedCrossRef Ardizzone S et al (2008) Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 40(Suppl 2): S253–S259PubMedCrossRef
16.
Zurück zum Zitat Orchard TR et al (2002) Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123: 714–718PubMedCrossRef Orchard TR et al (2002) Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 123: 714–718PubMedCrossRef
17.
Zurück zum Zitat Farhi D et al (2008) Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine 87: 281–293PubMedCrossRef Farhi D et al (2008) Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine 87: 281–293PubMedCrossRef
18.
Zurück zum Zitat Travis S et al (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 9: 715–720PubMedCrossRef Travis S et al (1997) Sweet’s syndrome: an unusual cutaneous feature of Crohn’s disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 9: 715–720PubMedCrossRef
19.
Zurück zum Zitat Orchard T (2003) Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 5: 512–517PubMedCrossRef Orchard T (2003) Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 5: 512–517PubMedCrossRef
20.
Zurück zum Zitat Juillerat P et al (2007) Extraintestinal manifestations of Crohn’s disease. Digestion 76: 141–148PubMedCrossRef Juillerat P et al (2007) Extraintestinal manifestations of Crohn’s disease. Digestion 76: 141–148PubMedCrossRef
21.
Zurück zum Zitat Bennett ML et al (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79: 37–46PubMedCrossRef Bennett ML et al (2000) Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine 79: 37–46PubMedCrossRef
22.
Zurück zum Zitat Brooklyn TN et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55: 505–509PubMedCrossRef Brooklyn TN et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55: 505–509PubMedCrossRef
23.
Zurück zum Zitat Dabade TS, Davis MD (2011) Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet’s syndrome). Dermatol Ther 24: 273–284PubMedCrossRef Dabade TS, Davis MD (2011) Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet’s syndrome). Dermatol Ther 24: 273–284PubMedCrossRef
24.
Zurück zum Zitat Trost LB, McDonnell JK (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81(959): 580–585PubMedCrossRef Trost LB, McDonnell JK (2005) Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 81(959): 580–585PubMedCrossRef
25.
Zurück zum Zitat Manganelli C, Turco S, Balestrazzi E (2009) Ophthalmological aspects of IBD. Eur Rev Med Pharmacol Sci 13 (Suppl 1): 11–13PubMed Manganelli C, Turco S, Balestrazzi E (2009) Ophthalmological aspects of IBD. Eur Rev Med Pharmacol Sci 13 (Suppl 1): 11–13PubMed
26.
Zurück zum Zitat Biancone L et al (2008) European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2: 63–92PubMedCrossRef Biancone L et al (2008) European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2: 63–92PubMedCrossRef
27.
Zurück zum Zitat Mintz R et al (2004) Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 10: 135–139PubMedCrossRef Mintz R et al (2004) Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 10: 135–139PubMedCrossRef
28.
Zurück zum Zitat Michaels A, Levy C (2008) The medical management of primary sclerosing cholangitis. Medscape J Med 10: 61PubMed Michaels A, Levy C (2008) The medical management of primary sclerosing cholangitis. Medscape J Med 10: 61PubMed
29.
Zurück zum Zitat Smith MP, Loe RH (1965) Sclerosing Cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 110: 239–246PubMedCrossRef Smith MP, Loe RH (1965) Sclerosing Cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 110: 239–246PubMedCrossRef
30.
Zurück zum Zitat Olsson R et al (1991) Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100: 1319–1323PubMed Olsson R et al (1991) Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100: 1319–1323PubMed
31.
Zurück zum Zitat Ghazale A et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134: 706–715PubMedCrossRef Ghazale A et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134: 706–715PubMedCrossRef
32.
Zurück zum Zitat Ashraf I et al (2012) Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol 31: 69–74PubMedCrossRef Ashraf I et al (2012) Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol 31: 69–74PubMedCrossRef
33.
Zurück zum Zitat Eaton JE et al (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106: 1638–1645PubMedCrossRef Eaton JE et al (2011) High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 106: 1638–1645PubMedCrossRef
34.
Zurück zum Zitat Barnabas A, Chapman RW (2012) Primary sclerosing cholangitis: is any treatment worthwhile? Curr Gastroenterol Rep 14: 17–24PubMedCrossRef Barnabas A, Chapman RW (2012) Primary sclerosing cholangitis: is any treatment worthwhile? Curr Gastroenterol Rep 14: 17–24PubMedCrossRef
35.
Zurück zum Zitat Barrie A, Regueiro M (2007) Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 13: 1424–1429PubMedCrossRef Barrie A, Regueiro M (2007) Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 13: 1424–1429PubMedCrossRef
36.
Zurück zum Zitat (o A) 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7–29, 2000: highlights of the conference. South Med J 94: 569–573 (o A) 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7–29, 2000: highlights of the conference. South Med J 94: 569–573
37.
Zurück zum Zitat Reinshagen M (2008) Osteoporosis in inflammatory bowel disease. J Crohns Colitis 2: 202–207PubMedCrossRef Reinshagen M (2008) Osteoporosis in inflammatory bowel disease. J Crohns Colitis 2: 202–207PubMedCrossRef
38.
Zurück zum Zitat Miheller P, Lorinczy K, Lakatos PL (2010) Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol 16: 5536–5542PubMedCrossRef Miheller P, Lorinczy K, Lakatos PL (2010) Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol 16: 5536–5542PubMedCrossRef
39.
Zurück zum Zitat Jahnsen J et al (1997) Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 40: 313–319PubMed Jahnsen J et al (1997) Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 40: 313–319PubMed
40.
Zurück zum Zitat Ghosh S et al (1994) Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 107: 1031–1019PubMed Ghosh S et al (1994) Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 107: 1031–1019PubMed
41.
Zurück zum Zitat Bernstein M, Irwin S, Greenberg GR (2005) Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol 100: 2031–2035PubMedCrossRef Bernstein M, Irwin S, Greenberg GR (2005) Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol 100: 2031–2035PubMedCrossRef
42.
Zurück zum Zitat Miheller P et al (2007) Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis 13: 1379–1384PubMedCrossRef Miheller P et al (2007) Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis 13: 1379–1384PubMedCrossRef
43.
Zurück zum Zitat Miehsler W et al (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53: 542–548PubMedCrossRef Miehsler W et al (2004) Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53: 542–548PubMedCrossRef
44.
Zurück zum Zitat Nguyen GC, Sam J (2008) Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 103: 2272–2280PubMedCrossRef Nguyen GC, Sam J (2008) Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 103: 2272–2280PubMedCrossRef
45.
Zurück zum Zitat Papay P et al (2012) Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis Papay P et al (2012) Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis
46.
Zurück zum Zitat Novacek G et al (2010) Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 139: 779–787, 787 e1PubMedCrossRef Novacek G et al (2010) Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 139: 779–787, 787 e1PubMedCrossRef
47.
Zurück zum Zitat Cohen AT et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (9610): 387–394PubMedCrossRef Cohen AT et al (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (9610): 387–394PubMedCrossRef
48.
Zurück zum Zitat Geerts WH et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl 6): 381S–453SPubMedCrossRef Geerts WH et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl 6): 381S–453SPubMedCrossRef
49.
Zurück zum Zitat Dobromirski M, Cohen AT (2012) How I manage venous thromboembolism risk in hospitalized medical patients. Blood 120: 1562–1569PubMedCrossRef Dobromirski M, Cohen AT (2012) How I manage venous thromboembolism risk in hospitalized medical patients. Blood 120: 1562–1569PubMedCrossRef
50.
Zurück zum Zitat Lloyd NS et al (2008) Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost 6: 405–414PubMedCrossRef Lloyd NS et al (2008) Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost 6: 405–414PubMedCrossRef
51.
Zurück zum Zitat Kahn SR et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141 (Suppl 2): e195S–e226S Kahn SR et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141 (Suppl 2): e195S–e226S
52.
Zurück zum Zitat Qaseem A et al (2011) Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 155: 625–632PubMedCrossRef Qaseem A et al (2011) Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 155: 625–632PubMedCrossRef
Metadaten
Titel
Therapie der extraintestinalen CED-Manifestationen
Eine schwierige Herausforderung
verfasst von
J. Zeitz
PD Dr. S.R. Vavricka
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Die Gastroenterologie / Ausgabe 3/2013
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-012-0726-2

Weitere Artikel der Ausgabe 3/2013

Der Gastroenterologe 3/2013 Zur Ausgabe

CME Zertifizierte Fortbildung

Komplikationen der Leberzirrhose

Mitteilungen der GARPS

Mitteilungen der GARPS

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.